AvalehtGSK • NYSE
add
GSK plc
Viimane sulgemishind
59,54 $
Tänane vahemik
58,05 $ - 59,07 $
Aasta vahemik
32,38 $ - 61,70 $
Turuväärtus
118,63 mld USD
Keskmine maht
6,42 mln
P/E suhe
15,43
Dividendimäär
3,07%
Uudised
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
| (GBP) | dets 2025info | Y/Y muutus |
|---|---|---|
Käive | 8,62 mld | 6,17% |
Põhitegevusega seonduv kulu | 4,57 mld | −0,28% |
Puhastulu | 636,00 mln | 53,62% |
Puhaskasumimarginaal | 7,38 | 44,71% |
Puhaskasum aktsia kohta | — | — |
EBITDA | 2,50 mld | 35,38% |
Tõhus maksumäär | 23,47% | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
| (GBP) | dets 2025info | Y/Y muutus |
|---|---|---|
Sularaha ja lühiajalised investeeringud | 3,41 mld | −21,27% |
Kogu vara | 61,12 mld | 2,78% |
Kõik kohustused | 45,16 mld | −2,62% |
Kogu omakapital | 15,96 mld | — |
Emiteeritud aktsiate arv | 4,01 mld | — |
Hinna ja väärtuse suhe P/B | 14,59 | — |
Varade tasuvus | 5,87% | — |
Kapitali tasuvus | 10,70% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
| (GBP) | dets 2025info | Y/Y muutus |
|---|---|---|
Puhastulu | 636,00 mln | 53,62% |
Põhitegevuse rahakäive | 2,28 mld | −2,19% |
Investeeringute raha | −933,00 mln | 16,62% |
Finantseerimise raha | −856,00 mln | −1,66% |
Raha ja raha ekvivalentide muutus | 448,00 mln | 19,47% |
Tasuta rahavoog | 1,15 mld | −49,69% |
Teave
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
Tegevjuht
Asutatud
27. dets 2000
Veebisait
Töötajate arv
68 629
